Titlebook: p53 in the Clinics; Pierre Hainaut,Magali Olivier,Klas G. Wiman Book 2013 Springer Science+Business Media New York 2013 TP53.cancer resear

eucalyptus

开花期女

慎重

machination

自由职业者

Assessing , Status in Human Tumors: Lessons from Breast Cancer,ssessing . mutation status in human tumors and the most commonly used techniques will be presented to show the advancement and current trends. . status is further discussed in the context of whole genome analysis, which may elucidate the . network, uncover gene profiles to substitute previous mutati

儿童

外观

, Gene Therapy for Cancer Treatment and Prevention,r . gene therapy to restore normal p53 function in cancer treatment. Several important principles were elucidated in preclinical tumor models which predicted the outcomes of subsequent clinical trials including synergistic antitumor activity for combined . gene therapy plus DNA damaging chemotherapy

interference

Upstream Targets in the p53 Pathway,cancer therapies. Both mutant and wild-type protein can be reactivated via direct binding of small molecules, but it is also possible to achieve this by targeting proteins involved in the regulation of p53. As many tumours contain wild-type p53 protein that is rendered inactive via disruption of its

离开

指耕作

Targeting Mutant p53 for Improved Cancer Therapy,53-dependent apoptosis in response to oncogenic stress and thus eliminate the tumor. Mutant p53 reactivation may also lead to inhibition of mutant p53 gain-of-function activities that promote tumor growth, and act synergistically with conventional chemotherapeutic agents and radiotherapy. Several sm